-
1دورية أكاديمية
المؤلفون: Di Paolo V; Laboratory of Drug Metabolism, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy. Electronic address: veronica.dipaolo@unipd.it., Ferrari FM; Department R&D, MeteRSit, Padova, Italy., Veronese D; Laboratory of Drug Metabolism, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy., Poggesi I; Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline S.p.A., Verona, Italy., Quintieri L; Laboratory of Drug Metabolism, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy. Electronic address: luigi.quintieri@unipd.it.
المصدر: Journal of pharmacological and toxicological methods [J Pharmacol Toxicol Methods] 2024 May-Jun; Vol. 127, pp. 107516. Date of Electronic Publication: 2024 May 20.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9206091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-488X (Electronic) Linking ISSN: 10568719 NLM ISO Abbreviation: J Pharmacol Toxicol Methods Subsets: MEDLINE
مواضيع طبية MeSH: Drug Interactions*/physiology , Cytochrome P-450 CYP2B6*/metabolism , Cytochrome P-450 CYP2B6*/genetics , Cytochrome P-450 CYP2C8*/metabolism , Cytochrome P-450 CYP2C8*/genetics , Algorithms* , Area Under Curve*, Humans ; Cytochrome P-450 CYP2C8 Inhibitors/pharmacology ; Cytochrome P-450 CYP2B6 Inhibitors/pharmacology ; Cytochrome P-450 CYP2B6 Inhibitors/pharmacokinetics ; Bayes Theorem
-
2دورية أكاديمية
المؤلفون: Bi YA; Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA., Jordan S; Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA., King-Ahmad A; Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA., West MA; Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA., Varma MVS; Pharmacokinetics, Dynamics, and Metabolism, Pfizer R&D, Pfizer Inc., Groton, Connecticut, USA.
المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jun; Vol. 115 (6), pp. 1336-1345. Date of Electronic Publication: 2024 Feb 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
مواضيع طبية MeSH: Liver-Specific Organic Anion Transporter 1*/metabolism , Liver-Specific Organic Anion Transporter 1*/antagonists & inhibitors , Drug Interactions* , Macaca fascicularis* , Cytochrome P-450 CYP2C8*/metabolism , Renal Insufficiency, Chronic*/metabolism , Hepatocytes*/metabolism , Hepatocytes*/drug effects , Rifampin*/pharmacology , Solute Carrier Organic Anion Transporter Family Member 1B3*/metabolism , Solute Carrier Organic Anion Transporter Family Member 1B3*/antagonists & inhibitors, Humans ; Animals ; Male ; Glycine/analogs & derivatives ; Glycine/pharmacokinetics ; Liver Diseases/metabolism ; Models, Biological ; HEK293 Cells ; Female ; Liver/metabolism ; Adult ; Cytochrome P-450 CYP2C8 Inhibitors/pharmacokinetics
-
3دورية أكاديمية
المؤلفون: Templeton IE; Certara, UK Ltd. (Simcyp Division), Sheffield, UK., Rowland-Yeo K; Certara, UK Ltd. (Simcyp Division), Sheffield, UK., Jones HM; Certara, UK Ltd. (Simcyp Division), Sheffield, UK., Endres CJ; Quantitative Pharmacology and Disposition, Seagen Inc., Bothell, Washington, USA., Topletz-Erickson AR; Quantitative Pharmacology and Disposition, Seagen Inc., Bothell, Washington, USA., Sun H; Quantitative Pharmacology and Disposition, Seagen Inc., Bothell, Washington, USA., Lee AJ; Quantitative Pharmacology and Disposition, Seagen Inc., Bothell, Washington, USA.
المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Feb; Vol. 115 (2), pp. 299-308. Date of Electronic Publication: 2023 Dec 08.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
-
4دورية أكاديمية
المؤلفون: Iga K; Pharmaceutical Research and Technology Unit, R & D Division, Pre-formulation Department, Towa Pharmaceutical Co., Ltd, Kyoto Research Park KISTIC #202, 134, Chudoji Minami-machi, Shimogyo-ku, Kyoto, 600-8813, Japan. kiga2020@outlook.jp., Kiriyama A; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo Kyotanabe-shi, Kyoto, 610-0395, Japan.
المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Jan; Vol. 63 (1), pp. 43-56. Date of Electronic Publication: 2023 Nov 03.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
-
5دورية أكاديمية
المؤلفون: Gaud N; Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: nilesh.gaud@doctoral.uj.edu.pl., Gogola D; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: dawid.gogola@ryvu.com., Kowal-Chwast A; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: anna.kowal-chwast@ryvu.com., Gabor-Worwa E; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: ewelina.gabor-worwa@ryvu.com., Littlewood P; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: peterlittlewood9@gmail.com., Brzózka K; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: krzysztof.brzozka@ryvu.com., Kus K; Drug Metabolism and Pharmacokinetics, Ryvu Therapeutics SA, Kraków, Poland. Electronic address: kamil.kus@ryvu.com., Walczak M; Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. Electronic address: walczak@uj.edu.pl.
المصدر: Drug metabolism and pharmacokinetics [Drug Metab Pharmacokinet] 2024 Aug; Vol. 57, pp. 101023. Date of Electronic Publication: 2024 May 28.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101164773 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-0920 (Electronic) Linking ISSN: 13474367 NLM ISO Abbreviation: Drug Metab Pharmacokinet Subsets: MEDLINE
مواضيع طبية MeSH: Rosiglitazone*/pharmacokinetics , Rosiglitazone*/metabolism , Rosiglitazone*/pharmacology , Cytochrome P-450 CYP2C8*/metabolism , Drug Interactions* , Models, Biological*, Humans ; Hypoglycemic Agents/pharmacokinetics ; Hypoglycemic Agents/metabolism ; Thiazolidinediones/pharmacokinetics ; Thiazolidinediones/metabolism
-
6دورية أكاديمية
المؤلفون: Almestica-Roberts M; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Nguyen ND; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Sun L; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Serna SN; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Rapp E; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Burrell-Gerbers KL; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Memon TA; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Stone BL; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Nkoy FL; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Lamb JG; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Deering-Rice CE; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Rower JE; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah., Reilly CA; Department of Pharmacology and Toxicology, Center for Human Toxicology (M.A.-R., N.D.N., L.S., S.N.S., E.R., K.L.B.-G., T.A.M., J.G.L., C.E.D.-R., J.E.R., C.A.R.) and Department of Pediatrics, School of Medicine (B.L.S., F.L.N.), University of Utah, Salt Lake City, Utah chris.reilly@pharm.utah.edu.
المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 836-846. Date of Electronic Publication: 2024 Jul 16.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE
مواضيع طبية MeSH: Asthma*/drug therapy , Asthma*/genetics , Asthma*/metabolism , Cytochrome P-450 CYP2C8*/genetics , Cytochrome P-450 CYP2C8*/metabolism , Bronchi*/drug effects , Bronchi*/metabolism , Bronchi*/cytology , Epithelial Cells*/drug effects , Epithelial Cells*/metabolism, Humans ; Child ; Male ; Female ; Adolescent ; Lipid Metabolism/drug effects ; Lipid Metabolism/genetics ; Inflammation/genetics ; Inflammation/metabolism ; Cells, Cultured ; Quinolines/pharmacology ; Polymorphism, Single Nucleotide ; Acetates ; Cyclopropanes ; Sulfides
-
7دورية أكاديمية
المؤلفون: Topletz-Erickson A; Clinical Pharmacology and Pharmacometrics, Seagen Inc., 21823 30th Drive SE, Bothell, WA, 98021, USA., Lee A; Translational ADME and PKPD, Seagen Inc., Bothell, WA, USA., Rustia EL; Clinical Development, Seagen Inc., Bothell, WA, USA.; Gilead Sciences, Seattle, WA, USA., Sun H; Translational ADME and PKPD, Seagen Inc., Bothell, WA, USA., Mayor JG; Clinical Development, Seagen Inc., Bothell, WA, USA., Abdulrasool LI; Clinical Development, Seagen Inc., Bothell, WA, USA., Walker L; Clinical Development, Seagen Inc., Bothell, WA, USA., Endres CJ; Clinical Pharmacology and Pharmacometrics, Seagen Inc., 21823 30th Drive SE, Bothell, WA, 98021, USA. CEndres@seagen.com.
المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2022 Oct; Vol. 61 (10), pp. 1417-1426. Date of Electronic Publication: 2022 Aug 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
مواضيع طبية MeSH: Cytochrome P-450 CYP2C8 Inducers* , Cytochrome P-450 CYP3A Inducers*/pharmacokinetics, ATP Binding Cassette Transporter, Subfamily B/metabolism ; Area Under Curve ; Cytochrome P-450 CYP2C8/metabolism ; Cytochrome P-450 CYP2C8 Inhibitors ; Cytochrome P-450 CYP2C9/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Digoxin ; Drug Interactions ; Gemfibrozil ; Healthy Volunteers ; Humans ; Itraconazole/pharmacology ; Midazolam/pharmacokinetics ; Oxazoles ; Pyridines ; Quinazolines ; Rifampin/pharmacology ; Tolbutamide
-
8دورية أكاديمية
المؤلفون: Sechaud R; Novartis Pharma AG, 4002, Basel, Switzerland. romain.sechaud@novartis.com., Gu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Rahmanzadeh G; Novartis Pharma AG, 4002, Basel, Switzerland., Taylor A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Chiparus O; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sharma GK; Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, 50081, India., Breitschaft A; Parexel International GmbH, 14059, Berlin, Germany., Menssen HD; Novartis Pharma AG, 4002, Basel, Switzerland.
المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 May; Vol. 93 (5), pp. 439-453. Date of Electronic Publication: 2024 Jan 25.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
مواضيع طبية MeSH: Bupropion*/pharmacokinetics , Bupropion*/administration & dosage , Cytochrome P-450 CYP2B6*/metabolism , Cytochrome P-450 CYP2B6*/genetics , Cytochrome P-450 CYP2C8*/metabolism , Cytochrome P-450 CYP3A*/metabolism , Drug Interactions* , Midazolam*/pharmacokinetics , Midazolam*/administration & dosage , Staurosporine*/analogs & derivatives , Staurosporine*/pharmacology , Staurosporine*/pharmacokinetics , Staurosporine*/administration & dosage, Humans ; Area Under Curve ; Contraceptives, Oral/administration & dosage ; Contraceptives, Oral/pharmacology ; Contraceptives, Oral/pharmacokinetics ; Drug Combinations ; Ethinyl Estradiol/pharmacokinetics ; Ethinyl Estradiol/administration & dosage ; Ethinyl Estradiol/pharmacology ; Healthy Volunteers ; Levonorgestrel/pharmacokinetics ; Levonorgestrel/administration & dosage ; Levonorgestrel/pharmacology ; Pioglitazone/pharmacology ; Pioglitazone/administration & dosage ; Pioglitazone/pharmacokinetics ; Male ; Female ; Adolescent ; Young Adult ; Adult ; Middle Aged
-
9دورية أكاديمية
المؤلفون: Camara MD; Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden.; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali., Zhou Y; Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden., De Sousa TN; Department of Microbiology and Tumor Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Molecular Biology and Malaria Immunology Research Group, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Brazil., Gil JP; Department of Microbiology and Tumor Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Institute of Hygiene and Tropical Medicine, Global Health and Tropical Medicine, Nova University of Lisbon, Lisbon, Portugal., Djimde AA; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Science, Techniques and Technologies, Bamako, Mali., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden. volker.lauschke@ki.se.; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. volker.lauschke@ki.se.; University of Tübingen, Tübingen, Germany. volker.lauschke@ki.se.
المصدر: Human genomics [Hum Genomics] 2024 Apr 22; Vol. 18 (1), pp. 40. Date of Electronic Publication: 2024 Apr 22.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Meta-Analysis; Research Support, N.I.H., Extramural
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101202210 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-7364 (Electronic) Linking ISSN: 14739542 NLM ISO Abbreviation: Hum Genomics Subsets: MEDLINE
مواضيع طبية MeSH: Cytochrome P-450 CYP2C8*/genetics , Alleles* , Carbamates* , Piperidines*, Humans ; Gene Frequency/genetics ; Polymorphism, Single Nucleotide/genetics ; Europe ; Thiazolidinediones/adverse effects
-
10دورية أكاديمية
المؤلفون: Yamazoe Y; Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai, 980-8578, Japan; Division of Risk Assessment, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kawasaki, 210-9501, Japan. Electronic address: yasushi.yamazoe.a4@tohoku.ac.jp., Yamamura Y; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan; Non-Clinical Regulatory Science, Applied Research & Operations, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan., Yoshinari K; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
المصدر: Drug metabolism and pharmacokinetics [Drug Metab Pharmacokinet] 2024 Apr; Vol. 55, pp. 100492. Date of Electronic Publication: 2023 Jan 20.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101164773 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-0920 (Electronic) Linking ISSN: 13474367 NLM ISO Abbreviation: Drug Metab Pharmacokinet Subsets: MEDLINE
مواضيع طبية MeSH: Cytochrome P-450 CYP2C8*, Ligands ; Catalytic Domain